The recall, dated Tuesday, August 25, involves two lots of Baxter International Inc.\u2019s 0.9% Sodium Chloride Injection because the product may contain fiberglass in the solution itself, the company said.<\/p>\n
\u201cIntravenous administration of 0.9% Sodium Chloride Injection containing fiberglass particulate matter may lead to serious adverse health consequences,\u201d the company said.<\/p>\n
The FDA report<\/a> said the possible contaminant could cause blockage and clotting of blood vessels, which could cut off blood flow to vital organs and lead to a life-threatening blood clot in the lungs, causing permanent organ damage or death in some cases.<\/p>\n Other reactions could include \u201clocal vein irritation, inflammatory reaction, aggravation of preexisting infections, and allergic reactions.\u201d However, no reports of adverse effects have been reported to the company as of Tuesday, August 25.<\/p>\n The recalled<\/a> lots were distributed between July 31, 2026, and August 3, 2026, to health care providers and distributors in more than a dozen states, including Texas.<\/p>\n \u201cThe product is indicated as a source of water and electrolytes and is also indicated for use as a priming solution in hemodialysis procedures,\u201d the FDA recall alert<\/a> stated.\u00a0<\/p>\n The lot numbers include Y495523 and Y495523A, with an expiration date of October 31, 2027.<\/p>\n The company said customers who received the products should immediately stop using them and return all affected units to Baxter. Customers with questions can call Baxter Healthcare Center for Service at 888-229-0001 between 7 a.m. and 6 p.m. Central Time, Monday through Friday.\u00a0<\/p>\n